Prostate Cancer
Seprase (FAP) is highly expressed in prostate cancer tumor-associated fibroblasts (CAFs) and directly drives tumor growth, invasion and metastasis. Furthermore, FAP is associated with poor prognosis in prostate cancer, making it a key target for intervention in the tumor microenvironment. Alfa Cytology offers one-stop services for seprase (FAP)-targeted drug development, tailored for prostate cancer. From molecular imaging to multi-platform drug development, we accelerate your pipeline with precision.
Introduction to Prostate Cancer
Seprase (FAP) is highly expressed in tumor-associated fibroblasts (CAFs), which are a major component of the prostate cancer stroma and account for a large proportion of the tumor volume.FAP directly drives tumor growth, invasion, and metastasis by promoting extracellular matrix (ECM) remodeling, angiogenesis, and immunosuppression. Furthermore, seprase (FAP) expression in metastatic denuded resistant prostate cancer (mCRPC) is significantly higher than in benign tissues and correlates with poor prognosis, making it a key target for intervention in the tumor microenvironment.
Fig. 1 Conventional hematoxilineosin and immunohistochemical stainings of PSMA and FAP expression in patients with newly diagnosed prostate cancer. (Kessel, K., et al. 2022)
Seprase (FAP)-Targeted Drug Development for Prostate Cancer
| Name | Indication | Company | Phase |
| 177Lu-LNC1004 | Solid tumors (including prostate cancer) | Dongcheng Pharma | Phase I |
| 177-FAP-2286 | Solid tumors (including prostate cancer) | Novartis | Phase II |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At Alfa Cytology, our experts have been working on the tumor microenvironment, driving translational medicine with cutting-edge science and focusing on the development of novel prostate cancer therapies that are precise and effective. We have a specialized platform to provide customized and comprehensive drug development services to meet your needs.
Multiple Diagnostic Development Services
Seprase (FAP)-Targeted Imaging Agent
Using advanced imaging modalities such as PET and SPECT, we provide FAP-targeted imaging services for improved detection and characterization of FAP-expressing tumors.
Theranostic Radiopharmaceuticals
Combining precision cancer care with today's most innovative radiopharmaceuticals, we deliver dual modality solutions for both diagnosis and therapy in FAP-expressing tumors.
Diverse Therapeutics Development Services
Our Prostate Cancer Modeling Services
In the field of targeted prostate cancer therapy, Alfa Cytology is the first to lay claim to the breakthrough target of seprase (FAP). Combined with our unique strengths in tumor stroma remodeling and radionuclide coupling (RDC) technology, we offer you a one-stop development service. Reach out to discuss collaboration opportunities and expedite your drug development process.
Reference
- Kessel, K., et al. Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging. Annals of nuclear medicine. 2022, 36(3): 293–301.
For research use only.